At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 6 enrolled
Drug / intervention
Axitinib (AG-013736)drug
Likely dose
Axitinib (AG-013736) 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Study In Patients With Advanced Solid Tumor To Evaluate The Pharmacokinetics And Safety Of AG-013736 At Single Doses Of 5 mg, 7 mg And 10 mg, And At Multiple Doses
In Brief
A Phase 1 clinical trial evaluating Axitinib (AG-013736) for Neoplasms. Completed, enrolled 6 participants across 1 site.
Detailed Summary
This study designed to evaluate the pharmacokinetics and safety of AG-013736 at single doses and multiple doses
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplasms
CountriesJapan
Collaborators--
Timeline
Phase 1CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2008
First PostedAug 2008
Primary CompletionApr 2010
TodayJul 2026
First PostedAug 1, 2008
Enrollment StartJul 1, 2008
Primary CompletionApr 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 17.9 years ago
Interventions
Axitinib (AG-013736)drug
Three single dose level of AG-013736 (5 mg, 7 mg and 10 mg) will be given for all patient. After single dosing at each dose level, multiple doses of 5 mg twice a day (BID) will be started.